Polymorphic drug metabolizing CYP-enzymes - A pathogenic factor in oral lichen planus?

Journal of Oral Pathology and Medicine

Volumn 38, Issue 1, 2009, Pages 63-71

  Kragelund, C ^a   Hansen, C ^b   Reibel, J ^a   Nauntofte, B ^a   Broesen, K ^c   Pedersen, A M L ^a   Smidt, D ^a   Eiberg, H ^b   Torpet, L A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

CYP; CYP2D6*4; Cytochrome P450; Molecular mimicry; Oral lichen planus; Polymorphisms

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; FISH OIL; HERBACEOUS AGENT; VITAMIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIET SUPPLEMENTATION; ENZYME METABOLISM; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MOUTH LICHEN PLANUS; PRIORITY JOURNAL;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; MOLECULAR MIMICRY; NONPRESCRIPTION DRUGS; PHARMACEUTICAL PREPARATIONS; PLANTS, MEDICINAL; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 58149242628     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2008.00702.x     Document Type: Article

References (43)

1. Eisen D. The evaluation of cutaneous, genital, scalp, nail, esophageal, and ocular involvement in patients with oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 88 : 431 6.
2. Zain RB, Ikeda N, Razak IA, et al. A national epidemiological survey of oral mucosal lesions in Malaysia. Community Dent Oral Epidemiol 1997 25 : 377 83.
3. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 White Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol 1986 61 : 373 81.
4. Axell T. A prevalence study of oral mucosal lesions in an adult Swedish population. Odontol Revy 1976 27 : 1 103.
5. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis 2005 11 : 338 49.
6. van der Meij EH, Reibel J, Slootweg PJ, van der Wal JE, de Jong WF, van der Waal I. Interobserver and intraobserver variability in the histologic assessment of oral lichen planus. J Oral Pathol Med 1999 28 : 274 7.
7. van der Meij EH, Schepman KP, Plonait DR, Axell T, van der Waal I. Interobserver and intraobserver variability in the clinical assessment of oral lichen planus. J Oral Pathol Med 2002 31 : 95 8.
8. Thornhill MH, Sankar V, Xu XJ, et al. The role of histopathological characteristics in distinguishing amalgam-associated oral lichenoid reactions and oral lichen planus. J Oral Pathol Med 2006 35 : 233 40.
9. McCartan BE, McCreary CE. Oral lichenoid drug eruptions. Oral Dis 1997 3 : 58 63.
10. Potts AJ, Hamburger J, Scully C. The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg Oral Med Oral Pathol 1987 64 : 541 3.
11. Hay KD, Reade PC. Methyldopa as a cause of oral mucous membrane reactions. Br Dent J 1978 145 : 195 203.
12. Singal A. Familial mucosal lichen planus in three successive generations. Int J Dermatol 2005 44 : 81 2.
13. Kofoed ML, Wantzin GL. Familial lichen planus. More frequent than previously suggested? J Am Acad Dermatol 1985 13 : 50 4.
14. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004 60 : 329 36.
15. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004 9 : 442 73.
16. Hasler JA, Estabrook R, Murray M, et al. Human cytochromes P450. Mol Aspects Med 1999 20 : 1 137.
17. Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002 72 : 429 37.
18. Boitier E, Beaune P. Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update. Clin Rev Allergy Immunol 2000 18 : 215 39.
19. Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003 170 : 1481 9.
20. Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006 130 : 868 82.
21. Oldstone MB. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr Top Microbiol Immunol 2005 296 : 1 17.
22. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991 88 : 1370 8.
23. Kragelund C, Thomsen CE, Bardow A, et al. Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes. Oral Dis 2003 9 : 177 87.
24. Thornhill MH, Pemberton MN, Simmons RK, Theaker ED. Amalgam-contact hypersensitivity lesions and oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003 95 : 291 9.
25. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. WHO. Histological typing of cancer and precancer of the oral mucosa. Berlin : Springer, 1997.
26. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Individual and population based risk factors of ischemic heart diseases. A 21-year follow-up of 12,000 men and women from the osterbro study. Ugeskr Laeger 2003 165 : 1353 8.
27. Flockhart DA Cytochrome P450 drug-interaction table. http://medicine. iupvi.edu/flockhart/table.htm. Version 4.0 [AUG 2007].
28. http://www.medicin.dk. Lægemiddelkataloget®.
29. Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf 2003 26 : 707 20.
30. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003 35 : 35 98.
31. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997 60 : 284 95.
32. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 1996 272 : 210 8.
33. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996 6 : 341 9.
34. Brosen K, Nielsen PN, Brusgaard K, Gram LF, Skjodt K. CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994 47 : 221 5.
35. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004 50 : 195 200.
36. Bathum L, Andersen-Ranberg K, Boldsen J, Brosen K, Jeune B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol 1998 54 : 427 30.
37. Pedersen RS, Verstuyft C, Becquemont L, Jaillon P, Brosen K. Cytochrome P4502C9 (CYP2C9) genotypes in a nordic population in Denmark. Basic Clin Pharmacol Toxicol 2004 94 : 151 2.
38. Kjaer SK, de Villiers EM, Haugaard BJ, et al. Human papillomavirus, herpes simplex virus and cervical cancer incidence in Greenland and Denmark. A population-based cross-sectional study. Int J Cancer 1988 414 : 518 24.
39. Arendorf TM, Walker DM. The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980 25 : 1 10.
40. Lodi G, Giuliani M, Majorana A, et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004 151 : 1172 81.
41. Farin FM, Bigler LG, Oda D, McDougall JK, Omiecinski CJ. Expression of cytochrome P450 and microsomal epoxide hydrolase in cervical and oral epithelial cells immortalized by human papillomavirus type 16 E6/E7 genes. Carcinogenesis 1995 16 : 1391 401.
42. Dorado P, Caceres MC, Pozo-Guisado E, Wong ML, Licinio J, LLerena A. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005 39 : 571 4.
43. Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005 12 : 254 61.